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Abstract: Clostridium botulinum Group I and Clostridium sporogenes are closely related bacteria
responsible for foodborne, infant and wound botulism. A comparative genomic study with 556 highly
diverse strains of C. botulinum Group I and C. sporogenes (including 417 newly sequenced strains) has
been carried out to characterise the genetic diversity and spread of these bacteria and their neurotoxin
genes. Core genome single-nucleotide polymorphism (SNP) analysis revealed two major lineages;
C. botulinum Group I (most strains possessed botulinum neurotoxin gene(s) of types A, B and/or
F) and C. sporogenes (some strains possessed a type B botulinum neurotoxin gene). Both lineages
contained strains responsible for foodborne, infant and wound botulism. A new C. sporogenes cluster
was identified that included five strains with a gene encoding botulinum neurotoxin sub-type B1.
There was significant evidence of horizontal transfer of botulinum neurotoxin genes between distantly
related bacteria. Population structure/diversity have been characterised, and novel associations
discovered between whole genome lineage, botulinum neurotoxin sub-type variant, epidemiological
links to foodborne, infant and wound botulism, and geographic origin. The impact of genomic and
physiological variability on the botulism risk has been assessed. The genome sequences are a valuable
resource for future research (e.g., pathogen biology, evolution of C. botulinum and its neurotoxin
genes, improved pathogen detection and discrimination), and support enhanced risk assessments
and the prevention of botulism.
Keywords: Clostridium botulinum; Botulism; Neurotoxins; Clostridium sporogenes; Genomes; Foodborne;
Infant; Wound
Key Contribution: Clostridium botulinum Group I and Clostridium sporogenes are closely related
bacteria responsible for foodborne, infant and wound botulism. Core genome single-nucleotide
polymorphism (SNP) analysis of 556 highly diverse strains of these bacteria characterised
population structure/diversity and discovered novel associations between genomic lineage, botulinum
neurotoxin sub-type variant, epidemiological links to foodborne, infant and wound botulism,
and geographic origin.
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1. Introduction
Clostridium botulinum Group I (also known as proteolytic C. botulinum) and Clostridium sporogenes
are closely related mesophilic bacteria that share genotypic and physiological characteristics, including
a highly proteolytic nature and the ability to form spores of high thermal resistance. C. botulinum
Group I is one of four distinct groups within the species C. botulinum, a polyphyletic taxon united
only by the ability to form the highly potent botulinum neurotoxin [1–5]. C. sporogenes has often
been perceived as a non-toxic close relative of C. botulinum Group I [6–13]. It is an important cause
of food spoilage [14–16], and used as a surrogate for C. botulinum Group I in food sterilisation
tests [7,14,15,17–20]. Recent findings, however, show that C. sporogenes is not merely a non-toxic form
of C. botulinum Group I [8,10,21–25]. Genetic analysis has revealed that both C. botulinum Group I and
C. sporogenes contain strains that either form or do not form botulinum neurotoxin. Most strains of
C. botulinum Group I (but not all) form botulinum neurotoxin, whilst some (but not most) C. sporogenes
strains also form botulinum neurotoxin [8,10,22,24,25]. If C. botulinum Group I and C. sporogenes
are considered separate species, then C. sporogenes represents another distinct bacterium that forms
botulinum neurotoxin [22,24–26].
Strains of C. botulinum Group I (and to a lesser extent C. sporogenes) are a major cause of the
three most frequent types of botulism in humans (foodborne, infant and wound botulism) and are
also responsible for botulism in animals [4,5,27–30]. Foodborne botulism is a severe, and often lethal,
neuroparalytic intoxication potentially caused by the consumption of as little as 50 ng of botulinum
neurotoxin [5,31]. Spores of C. botulinum Group I are the target of the Botulinum cook (121 ◦C/3 min)
given to low acid canned foods [4,5]. Foodborne botulism outbreaks have been associated with a
failure to apply the Botulinum cook to canned or bottled foods, and also with temperature abuse of
products intended to be stored chilled [3,5,32–36]. The commercial implications of foodborne botulism
outbreaks can be significant [4,5], and continued extreme vigilance is important to ensure that the
incidence of foodborne botulism is minimised. Infant and wound botulism are both infections in
which the bacterium multiplies and forms botulinum neurotoxin in the body. Infant botulism results
from the absorption of botulinum neurotoxin formed by the bacterium following colonization of the
intestinal tract of infants under twelve months. Honey has been identified as one source of the bacterial
spores. Wound botulism ensues following the formation of botulinum neurotoxin by the bacterium
multiplying in a wound. Initial cases were associated with traumatic injury, but over the last few
decades there has been an increase in cases associated with injectable drug abuse [5,27,37,38].
Botulinum neurotoxins are zinc metalloproteases that ultimately reach the nerve cell cytoplasm
where they specifically cleave SNARE proteins involved in release of the neurotransmitter, acetylcholine,
resulting in a severe and often deadly flaccid muscle paralysis known as botulism [39,40]. More than
a century ago, two distinct botulinum neurotoxin serotypes were identified using specific antisera
to neutralise botulinum neurotoxin in animal tests [27,41,42]. Burke referred to these as serotypes A
and B [41]. Today, many botulinum neurotoxin serotypes and more than 40 botulinum neurotoxin
sub-types are recognised [43–46]. A majority of botulinum neurotoxin sub-types have been identified
through the sequencing of genes encoding botulinum neurotoxins, and the derivation of the amino acid
sequence. Most sub-types differ by at least 2.6% in amino acid sequence from another sub-type [45,46],
and sub-types of botulinum neurotoxins serotypes A and B have been shown to exhibit distinct
functional and toxicological properties [47–51]. Each botulinum neurotoxin sub-type comprises a
series of variants with unique amino acid sequence.
The strains examined in the present study possess up to three neurotoxin genes, and form up
to three neurotoxins of type A, B and/or F. Strains with two neurotoxin genes form either one active
toxin (e.g., type A(B) strains possess a type A and type B neurotoxin gene, but only form type A
neurotoxin) or two active toxins (e.g., type Bf strains form a greater amount of type B neurotoxin
than type F neurotoxin). In the present study, strains are referred to by their type or sub-type of
botulinum neurotoxin gene(s), e.g., type A strains possess a gene encoding botulinum neurotoxin type
A, B5F2 strains possess genes encoding botulinum neurotoxin sub-types B5 and F2. The botulinum
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neurotoxin is accompanied by accessory proteins (notably, non-toxic-non-haemagglutinin (NTNH))
in a series of toxin complexes that are encoded by genes located in either a ha cluster or an orfX
cluster. The ha cluster includes genes encoding the neurotoxin (all type B neurotoxins and some type A
neurotoxins), NTNH, three haemagglutinins, and a positive regulator. The orfX cluster includes genes
encoding the neurotoxin (all type F neurotoxins and other type A neurotoxins), NTNH, a positive
regulator, and four open reading frames of unknown function [3,43–46]. The neurotoxin gene(s) in
C. botulinum Group I and C. sporogenes can be located on the chromosome or a plasmid.
The purpose of the present study was to provide insights into the genetic diversity and spread
of strains of C. botulinum Group I and C. sporogenes and their neurotoxin genes. The genomes of 417
newly sequenced highly diverse strains (isolated from 24 countries and six continents over a period
of more than one hundred years) has been supplemented with 139 genomes publicly available in
Genbank. This represents the most comprehensive comparative genomic study of these bacteria
currently undertaken. Furthermore, the 556 genome sequences also represent a valuable resource,
contributing to future genomic, transcriptomic, proteomic and systems biology endeavours such
as dissecting the evolution of C. botulinum Group I and C. sporogenes and their neurotoxin genes,
the analysis of spore properties, regulation of neurotoxin formation, and other characteristics important
for pathogen transmission, and also the targeting of PCR assays to detect, trace and discriminate
strains [15,17,52–56]. These findings may add to future risk assessments and to the prevention of
botulism in humans and animals.
2. Results and Discussion
2.1. Overview of Diversity of Genomes and Neurotoxins
Publication of genome sequences of C. botulinum Group I began with that of strain ATCC 3502
(Hall A strain 174) [57], and at the start of this work there were 139 genomes publicly available in
Genbank. This sequence information has accelerated studies into the diversity and phylogenetic
relationship of strains of C. botulinum Group I and C. sporogenes [5,22,24,25,29,46,57–63]. Sequencing
of botulinum neurotoxin genes/clusters has provided insight into the diversity and evolution of
encoded neurotoxin serotypes, sub-types and variants [45]. In the present study, the genomic diversity,
phylogenetic relationship and botulinum neurotoxin genes/clusters have been characterised for
556 strains of C. botulinum Group I and C. sporogenes (Table S1). This includes 417 newly sequenced
strains, and considerably increases the number of publicly available genome sequences for C. botulinum
Group I and C. sporogenes. The strains were from a wide geographical area (24 countries from Europe
(predominantly the UK), Asia, Africa, Australasia, north America and south America; Figure 1).
Seventy-three strains were associated with foodborne botulism, 70 strains with infant botulism,
and 82 strains with wound botulism (Table S1). A further 139 strains were non-clinical isolates not
associated with botulism in humans, and the status of the remaining isolates is unknown.
This study has included a number of isolates associated with UK cases of foodborne, infant and
wound botulism, and also some UK non-clinical isolates (Table S1). Botulism incidents reported in
the UK between 1989 and 2019 are summarized in Table 1, with details of initial cases described
previously [64–66]. Recent cases of foodborne botulism have often been associated with the consumption
of imported food and have been associated with strains possessing genes encoding botulinum toxin
sub-types A1, B1, B2 and B5F2 (Table 1). Sporadic cases of infant botulism continue to be recorded
and are usually associated with known risk factors such as weaning, contact with dusty environment
during travel and feeding honey to the infant. Strains possessing genes encoding botulinum toxin
sub-types A2, B2, B5 and B5F2 have been associated with infant botulism between 1989 and 2019
(Table 1). There have been several outbreaks of wound botulism related to injectable drug use, with the
first UK case reported in 2000. Several wound botulism outbreaks often involving multiple patients are
indicated in some years. The most recent outbreak of wound botulism in Scotland in injectable drug
users occurred due to a large contaminated batch of heroin [67]. A1B5, A5B2, A5B3 and B3 strains
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have been associated with wound botulism (Table 1). A single case of adult colonization botulism was
recorded in 2018 (Table 1).Toxins 2019, 11, x FOR PEER REVIEW 4 of 29 
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Figure 1. Geographical locations and heat map of C. botulinum Group I and C. sporogenes strains included
in the present study. A total of 359 strains were attributed to a geographical location. Further details
about individual isolates are given in Table S1. For each specified country, the detected botulinum
neurotoxin genes for isolates are indicated (in black; with NT = no toxin gene), and the types of botulism
are shown in colour (N = non-clinical; I = infant botulism; U = unknown; F = foodborne botulism;
W = wound botulism).
Table 1. Summary of botulism cases recorded in the UK between 1989 and 2019. a Confirmed case:
diagnosis of botulism confirmed by laboratory testing (detection of botulinum toxin by bioassay or gene
by PCR). Probable case: a clear clinical diagnosis of botulism, laboratory tests either not undertaken
or negative (e.g., suboptimal or delayed sampling). b Early UK cases of foodborne botulism and
infant botulism were summarized previously [65,66]. c unknown. d not tested in the present study.
e Clostridium botulinum Group II sub-type B4 [2]. f Clostridium butyricum. g Wound botulism (injectable
drug use) data include the number of confirmed cases, with number of probable cases in parenthesis.
The number of confirmed cases for each botulinum toxin type from the outbreak investigation, and the
number of sequenced isolates for each botulinum toxin gene sub-type are shown in parentheses.
Year Confirmed Cases(Probable Cases) a
Botulinum Toxin
Type(s) From
Outbreak
Investigation
Botulinum Toxin
Gene Sub-type(s)
Detected in
This Study
Comments
Foodborne botulism b
1989 27 B B5F2 Commercial hazelnut yoghurt
1998 2 B B2 Bottled mushrooms (Italy)
2003 1 B B1 Sausage (Poland)
2004 1 un c nt d Hummus
2004 1 A nt Recent travel to Georgia
2005 1 B e nt Home preserved pork (Poland)
2010 1 B nt Recent travel to Algeria
2011 3 A A1 Commercial korma sauce
2012 1 B B2 Olives (Italy)
2013 1 un nt Mushroom (Poland)
2016 1 B nt Tuna (Italy)
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Table 1. Cont.
Year Confirmed Cases(Probable Cases) a
Botulinum Toxin
Type(s) From
Outbreak
Investigation
Botulinum Toxin
Gene Sub-type(s)
Detected in
This Study
Comments
Infant botulism b
1989 1 B nt Travel to Yemen, fed honey
1993 1 B B2 Travel to Spain
1994 1 A nt Fed honey, weaning
2001 1 B nt Weaning, infant formula milk
2007 1 A A2 Weaning
2007 1 B B2 Weaning
2009 1 A A2 Fed honey
2009 1 A A2 Fed honey
2010 1 E f nt Fed honey, kept terrapins
2011 1 A A2 Fed honey
2011 1 A A2 Fed honey
2011 1 B B2 Breast and bottle fed, dusty home
2012 1 B B5 Travel, dusty hostel rooms
2013 1 Bf B5F2 Fed honey
2013 1 Bf B5F2 Weaning
2017 1 B nt Travel to Western USA
2018 1 B nt Weaning
Intestinal colonisation botulism
2018 1 un nt Bowel obstruction, several co-morbidities
Wound botulism g
2000 3 (2) A A5B3(1)
2001 3 (1) A nt
2002 14 (6) A(12), B(2) nt
2003 7 (8) A(6), AB(1) nt
2004 15 (26) A(13), B(1), AB(1) A5B2(33), A5B3(1)
2005 6 (22) A(5), B(1) A5B2(2)
2006 9 (21) A(6), B(1), AB(2) A5B2(1), A5B3(4), B3(1)
2007 3 A(3) A5B2(2)
2008 4 A(1) nt
2009 12 (8) A(4), B(7), un(1) A1B5(3), B3(5)
2010 3 A(1), B(1), un(1) A5B2(1), B3(2)
2012 1 (2) A A5B3(1)
2013 2 (2) A (1), B (1) A5B2(1)
2014 2 (3) B B3(3)
2015 19 (28) B(16), un(2) B3(13) Large outbreak related to batch ofcontaminated heroin
2016 5 (2) B B3(1)
2017 1 (1) B nt
2018 2 (2) B nt
2019 1 (1) B nt
The 556 strains were assigned to one of two major lineages (C. botulinum Group I or C. sporogenes)
based on an analysis of core genome single nucleotide polymorphisms (SNPs) following whole genome
sequencing, and in silico multi-locus sequence typing (MLST) following the scheme of Jacobson et al. [68].
Each lineage comprised a series of distinct clusters (Figure 2). This is consistent with observations
made previously that have largely been carried out on a smaller number of and/or less diverse
strains [3,5,7,8,22,24,25,29,43,44,46,58,60,62,68]. The genome of 95% (429 out of 452) of strains assigned
to the C. botulinum Group I lineage possessed a botulinum neurotoxin gene or genes, while the genome
of only 19% (20 out of 104) of strains assigned to the C. sporogenes lineage possessed a botulinum
neurotoxin gene. This assignation resulted in a few strains now being designated as C. botulinum Group
I and not C. sporogenes, or vice-versa. For example, strains 2345, AM370, and B2 450 were all previously
described as C. botulinum Group I on the basis of their ability to form botulinum neurotoxin [8,25,29,59],
but in the present study are located within the C. sporogenes lineage as their genome closely aligns with
that of other strains of C. sporogenes.
Clusters of strains can be identified in the two lineages, with most clusters dominated by strains
possessing genes that encode the same botulinum neurotoxin sub-type(s). There are also, however,
examples of genes encoding the same botulinum neurotoxin sub-type(s) being located in different
genomic backgrounds, indicating frequent horizontal movement of botulinum neurotoxin genes
between clusters (Figure 2). A majority of genomes (354) possessed a single gene encoding a botulinum
neurotoxin (type A, 183 strains; type B, 154 strains; type F, 17 strains), while 89 strains possessed two
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genes encoding botulinum neurotoxins, and the genome of six strains included three genes encoding
botulinum neurotoxins. The present study did not determine whether the presence of a neurotoxin gene
was associated with formation of botulinum neurotoxin. The genomes of 107 strains did not possess a
gene encoding botulinum neurotoxin. The genomes of all strains were searched using an approach
previously used to discover a novel putative botulinum neurotoxin gene in Enterococcus [69], but this
failed to reveal genes that might encode previously undescribed botulinum neurotoxin serotypes or
sub-types. Novel botulinum neurotoxin sub-type variants were identified, each with unique coding
(and predicted amino acid) sequence.Toxins 2019, 11, x FOR PEER REVIEW 7 of 29 
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right-hand column.
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2.2. Diversity and Phylogeny of C. botulinum Group I type A Strains and Their Botulinum Neurotoxin Genes
Eight sub-types of botulinum neurotoxin type A (A1 to A8) are currently recognised.
These sub-types have an amino acid difference of 2.9–15.6%, and within sub-type differences of
0.1–2.5% [45]. The genome of 271 strains examined in the present study contained a type A neurotoxin
gene. For 183 strains, the type A neurotoxin gene was the only neurotoxin gene present, with 88 strains
containing an additional neurotoxin gene(s) (Figure 2). Type A neurotoxin genes were located in strains
within the C. botulinum Group I lineage, but not the C. sporogenes lineage (Figure 2). Strains possessing
a gene encoding the same type A neurotoxin sub-type were located together in a series of discrete
clusters. However, strains within these individual clusters were often more closely related to strains
with other neurotoxin genes or no neurotoxin gene, than to strains in other clusters with the same
sub-type A neurotoxin gene (Figure 2). The presence of genes encoding the same botulinum neurotoxin
sub-type A gene in different genomic backgrounds indicates horizontal transfer of type A botulinum
neurotoxin genes between clusters.
The genome of 84 strains examined in the present study encoded a gene for botulinum neurotoxin
sub-type A1 (Figure 2). Genes encoding sub-type A1 neurotoxin were the only botulinum neurotoxin
genes located in either a ha or orfX neurotoxin gene cluster. Three major variant groupings of botulinum
neurotoxin sub-type A1 were recognised, and these were encoded by A1B5 strains, A1 (ha) strains
and A1 (orfX) strains (Figure 3, Table S3). This is as reported previously [3,22,45], with no new
major variant grouping identified. Core genome SNP analysis separated strains with a sub-type A1
neurotoxin gene into five clusters within C. botulinum Group I. Two clusters contained A1B5 strains,
two clusters contained A1 (ha) strains, while all A1 (orfX) strains were located in a single cluster
(Figure 2). A1B5 strains possessed a genome that encoded a sub-type A1 neurotoxin (central sub-type
A1 variant group in Figure 3 and Table S3) located in an orfX neurotoxin gene cluster, and also a
putative sub-type B5 neurotoxin. Eighteen strains belonged to one cluster and MLST ST-4 or ST-6,
while two strains belonged to the second cluster and MLST ST-10 (Figure 2, Table S2). Previous studies
found that many other A1B5 strains also belonged to ST-4 [68,73]. A1B5 strains were associated with
foodborne botulism in Ireland (in 2006) and USA, infant botulism in UK (in 1978) and USA, and wound
botulism in UK (in 2009) (Table 1 and Table S1) [65].
Sixty-three A1 (ha) strains possessed a single gene encoding botulinum neurotoxin belonging
to the upper sub-type A1 variant group in Figure 3 and Table S3 (in a ha neurotoxin gene cluster).
These strains were separated into two distinct clusters by core genome SNP analysis (Figure 2).
A majority of strains (54) belonged to one cluster and MLST ST-1 or ST-9, while a minority of strains
(seven) were present in a second cluster and MLST ST-19 (Figure 2, Table S2). Strains were associated
with foodborne botulism, including the 2011 UK outbreak involving three children who consumed
korma sauce (Table 1) [74], and various incidents in the USA, but not with wound or infant botulism.
Non-clinical isolates with genes encoding this variant were from Sweden, Kazakhstan, USA and
Netherlands (Table S1). Mazuet et al. [29] reported on a number of similar sub-type A1 (ha) strains
that belonged to MLST ST-1 or ST-19 and were associated with foodborne botulism or animal botulism
in France. The fifth cluster comprised three closely related strains (Figure 2), with a gene encoding
sub-type A1 neurotoxin (lower sub-type A1 variant in Figure 3 and Table S3) in an orfX neurotoxin
cluster (A1 (orfX) strains). Two of the three strains were associated with foodborne botulism, and the
third is a non-clinical isolate (Figure 2). The present study concurred with previous reports that A1
(orfX) strains were more closely related to strains of other sub-types (e.g., A4B5, B5F2) than to other
sub-type A1 strains [8,25,60,75,76].
A gene encoding sub-type A2 neurotoxin was present in 128 strains (Figure 3), some of which were
associated with foodborne or infant botulism, but not wound botulism (Figures 2 and 3). All sub-type
A2 neurotoxin genes were located in an orfX neurotoxin gene cluster. Some strains contained additional
type B or type F neurotoxin gene(s) (Figure 2). Sub-type A2 strains separated into six clusters within
C. botulinum Group I (Figure 2). A majority of strains shared a common genomic background (upper
cluster in Figure 2), and a gene encoding the most frequently recorded sub-type A2 botulinum
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neurotoxin variant (upper variant group in Figure 3, Table S3). These strains belonged to MLST
ST-2, ST-22 and ST-26 (Table S2). Sub-type A2 strains examined in the present and a previous study
principally belonged to ST-2 and ST-26 [77]. However, an additional fifteen strains examined in the
present study with more distant genomic backgrounds according to core genome SNP analysis and
MLST analysis (ST-7, ST-28, ST-38, ST-61, ST-85) (Figure 2, Table S2) also possessed a gene encoding this
sub-type A2 neurotoxin variant. The gene encoding this sub-type A2 neurotoxin variant has therefore
moved between distantly related C. botulinum Group I strains by horizontal gene transfer. Strains with
this sub-type A2 variant gene were associated with foodborne botulism, all of the infant botulism cases
associated with sub-type A2 strains, and there were also non-clinical isolates. This included strain
Mauritius that was associated with an outbreak of foodborne botulism in the UK in 1955 following
consumption of pickled fish prepared in the Indian Ocean island of Mauritius [66], and strains
responsible for five cases of infant botulism in the UK (Table 1) [65,78], and infant botulism in Japan
and USA [79]. Non-clinical isolates included strains from Argentina [23,25], and two strains isolated
in our laboratory in 2015 from soil samples from Uganda (Stringer SC and Peck MW, unpublished
results). Strain CDC 53174 that was isolated from stool sample in Uganda and our two sub-type A2
strains from Uganda (IFR 15/031 and 16/622) all belong to ST-28 [77]. The first reported outbreak of
foodborne botulism in Uganda involved a strain of C. botulinum Group I type A [80]. Few strains of
C. botulinum have been isolated from Africa, and it is noteworthy that the genomic background and
neurotoxin sub-type variant align with that found in other strains from around the world.
All but one of the 44 strains with a genome encoding the second most frequently recorded sub-type
A2 botulinum neurotoxin variant (second variant group in Figure 3, Table S3) shared a common
genomic background, as revealed by core genome SNP analysis (Figure 2). The strains were isolated
from several countries including UK, Denmark, Norway, Canada and Japan, with none known to be
associated with botulism (Figure 2, Table S1). Single, distantly related, strains possessed genomes
encoding each of the other two sub-type A2 botulinum neurotoxin variants. A strain associated with
an outbreak of foodborne botulism involving mascarpone cheese in Italy in 1996 [59] encoded the sole
example of the third sub-type A2 variant (third variant group in Figure 3, Table S3). A strain associated
with an outbreak of foodborne botulism involving home-canned meat in Italy in 1993 [59] provided
the only example of the fourth sub-type A2 botulinum neurotoxin variant (fourth variant group in
Figure 3, Table S3). These strains appeared to be more closely related to strains with other botulinum
neurotoxin genes, than to each other or to other strains that possessed a gene encoding botulinum
sub-type A2 neurotoxin (Figure 2).
Core genome SNP analysis and MLST analysis showed that strains with a gene encoding botulinum
neurotoxin sub-type A3 were present in two distinct C. botulinum Group I clusters (Figure 2). Strains in
the upper cluster (Figure 2) were non-clinical isolates from Argentina [23,25]. These strains belonged
to MLST ST-2 or ST-25 (Table S2), and possessed a gene encoding the lower variant of botulinum
neurotoxin sub-type A3 in Figure 3 (Table S3). Three further sub-type A3 strains from Argentina also
belonged to ST-25 [77]. Strains in the lower cluster (Figure 2) included isolates derived from the first
reported foodborne botulism outbreak in the UK at Loch Maree in 1922 [66,81], and also included a UK
non-clinical isolate. These strains belonged to MLST ST-3 (Table S2), and possessed a gene encoding a
second variant of botulinum neurotoxin sub-type A3 (upper variant in Figure 3, Table S3). Strains within
each of these two sub-type A3 genomic clusters were more closely related to strains with other botulinum
neurotoxin genes, than to strains in the other sub-type A3 genomic cluster. Botulinum neurotoxin
sub-types A3 and A4 were encoded by genes located in an orfX neurotoxin gene cluster. Two closely
related strains, as determined by core genome SNP analysis and MLST analysis (ST-7) possessed a
genome encoding botulinum neurotoxins sub-type A4 and sub-type B5 (Figure 2). Both strains were
associated with infant botulism; strain 657 in Texas in 1976 [82], and strain SRR8527662 in Ireland in
2014 (Table S1). A single variant of botulinum neurotoxin sub-type A4 was identified (Figure 3).
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Wound botulism was first reported in the UK in 2000. Cases f wound botulism reported between
2000 and 2004 were mainly associated with isolates forming type A neurotoxin, with a few isolates
forming type B neurotoxin [64,83]. A detailed analysis of isolates implicated in UK wound botulism
cases between 2000 and 2019 has shown that sub-type A5 strains were responsible for a number of
time-separated wound botulism outbreaks (Table 1). All UK cases of wou d botulis were associated
with injectable drug abuse, with the drugs a d associated s ra ns believed to originate in Asia [8,83].
Genes encoding the sub-type A5 neurotoxin and a truncated sub-type B2 or B3 neurotoxin were
co-located in a ha neurotoxin gene cluster, as described previously [8,29,84–86]. The truncated B2 and
B3 genes were of similar length. Two variants of sub-type A5 neurotoxin were identified (Figure 3).
Strains either contained genes encoding sub-type A5 neurotoxin belonging to the upper variant group
in Figure 3 and a truncated sub-type B2 neurotoxin, or sub-type A5 neurotoxin belonging to the lower
variant group in Figure 3 and a truncated B3 neurotoxin. The A5B2 strains were associated with
wound botulism cases in the UK between 2004 and 2013 (Table 1), wound botulism in Switzerland in
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2000, and foodborne botulism in France in 2011 [29]. Core genome SNP analysis and MLST analysis
established that most A5B2 strains (including all associated with wound botulism) were closely related,
and belonged to MLST ST-47 (Figure 2, Table S2). Two A5B2 strains (including one associated with
foodborne botulism) were more distantly related according to core genome SNP analysis and belonged
to different MLST sequence types (ST-46 and ST-86). The A5B3 strains were associated with wound
botulism cases in the UK between 2000 and 2012, and were closely related, based on core genome SNP
analysis and belonged to MLST ST-16 (Figure 2, Table S2).
2.3. Diversity and Phylogeny of C. botulinum Group I type B Strains and Their Botulinum Neurotoxin Genes
The eight sub-types of botulinum neurotoxin type B (B1 to B8) are less diverse than those of type A
or type F, with an amino acid difference of 1.6–7.1%, and within sub-type differences from 0.1–2.1% [45].
The genome of 239 strains examined in the present study contained a type B neurotoxin gene (Figure 2);
with 154 strains containing only a type B neurotoxin gene, and 85 strains containing an additional type
A or type F neurotoxin gene (Figure 2). All type B neurotoxin genes were located in a ha neurotoxin
gene cluster. Strains with genomes encoding botulinum neurotoxin type B belonged to the C. botulinum
Group I lineage or the C. sporogenes lineage (Figure 2). Strains with a similar genomic background
often possessed the same sub-type B neurotoxin gene but were also closely related to strains with other
or no neurotoxin genes (Figure 2). The same sub-type B botulinum neurotoxin gene was also located in
strains with distant genomic backgrounds, providing evidence for horizontal gene transfer.
The genome of 37 strains of C. botulinum Group I or C. sporogenes included a gene encoding
botulinum neurotoxin sub-type B1 (Figure 2), and it was the only botulinum neurotoxin gene in
these strains. Core genome SNP analysis revealed that these strains formed four clusters (Figure 2),
that did not entirely align with the four sub-type B1 neurotoxin variants (Figure 4, Table S3). The upper
C. botulinum Group I cluster in Figure 2 includes closely related strains that belonged to MLST ST-30
(Table S2) and were associated with foodborne or infant botulism in the USA (Table S1). These strains
possessed a gene encoding the same variant of sub-type B1 (second variant in Figure 4, Table S3).
Strains in the second C. botulinum Group I cluster belonged to MLST ST-34 (Figure 2, Table S2), and were
associated with foodborne botulism outbreaks in USA and UK non-clinical isolates. These strains
possessed a gene encoding one of two sub-type B1 variants (either upper variant or lower variant
(Figure 4)). Strains located within the C. sporogenes lineage exclusively possessed a gene encoding the
third sub-type B1 variant (Figure 4, Table S3), and separated into two clusters, both distantly related to
sub-type B1 strains within the C. botulinum Group I lineage (Figure 2).
Core genome SNP analysis revealed that the 119 strains that possessed a sub-type B2 neurotoxin
gene fell into eleven clusters that were very widely distributed amongst both the C. botulinum Group
I and C. sporogenes lineages, and that these strains were often closely related to strains with another
botulinum neurotoxin gene or no botulinum neurotoxin gene (Figure 2). The validity of these clusters
was supported by MLST analysis (Table S2). The presence of a sub-type B2 neurotoxin gene in many
different genomic backgrounds indicates significant horizontal transfer of this botulinum neurotoxin
gene between distantly related strains of both C. botulinum Group I and C. sporogenes. Genes encoding
sub-type B2 neurotoxin have been identified in isolates from around the world, including strains
associated with foodborne, infant and wound botulism (Figure 2). Some of these strains contained
additional neurotoxin-encoding genes (Figure 2). Most strains possessed a gene encoding a complete
sub-type B2 neurotoxin, although some strains possessed a gene encoding a truncated sub-type B2
neurotoxin. Strains with genes encoding a complete sub-type B2 neurotoxin (lower variant grouping
in Figure 4, Table S2) formed six clusters in C. botulinum Group I and two clusters in C. sporogenes
(Figure 2). Fourteen isolates were from foodborne botulism outbreaks, including a 1998 UK outbreak
associated with the consumption of home-preserved bottled mushrooms in oil brought back from
Italy [66], a 2012 UK outbreak associated with consumption of olives from Italy (Table 1), and 2013
French outbreak associated with the consumption of home-canned beans [29]. Eighteen isolates were
associated with infant botulism including three cases reported in the UK (Table 1) and one case in
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Greece [65]. Two further isolates were from wound botulism cases in Italy [59]. Non-clinical isolates
included two strains isolated in our laboratory from Ugandan soil samples (Stringer SC and Peck
MW, unpublished results), and other non-clinical isolates from UK, Poland, Spain, and USA (Table S1).
Some strains possessed genes encoding a truncated sub-type B2 neurotoxin and a complete sub-type
A5 neurotoxin co-located in a ha neurotoxin gene cluster (Figure 2). Closely related variants of the
truncated sub-type B2 neurotoxin were identified (upper grouping in Figure 4). Core genome SNP
analysis established that these strains formed three clusters, with most strains closely related and
belonging to MLST ST-47, including those associated with UK cases of wound botulism between 2004
and 2013 (Table 1), and a single strain associated with wound botulism in Switzerland in 2000 (Figure 2,
Table S2). Two additional strains (including one associated with foodborne botulism in France in
2011 [29]) were more distantly related according to core genome SNP analysis (Figure 2) and belonged
to different MLST sequence types (ST-46 and ST-86).
Thirty-nine strains that possessed an entire or truncated sub-type B3 neurotoxin gene fell into
three clusters within the C. botulinum Group I lineage, but not the C. sporogenes lineage (Figure 2).
Most of these strains were associated with wound botulism (Figure 2). The upper cluster (Figure 2)
contained A5B3 strains, with the gene encoding a truncated variant of the sub-type B3 neurotoxin
(third variant in Figure 4, Table S3) co-located with a sub-type A5 neurotoxin gene in an ha cluster.
These strains were associated with UK outbreaks of wound botulism in 2000, 2004, 2006, and 2012
(Table 1). The central cluster in Figure 2 contained 26 strains with a gene encoding an entire sub-type
B3 neurotoxin belonging to one of the upper two variants in Figure 4 (Table S3). These strains were
associated with outbreaks of wound botulism in UK (2006, 2009, 2010, 2014, 2015, and 2016; Table 1)
and in Germany (2016). The 2016 wound botulism outbreaks in Germany and the UK will be described
elsewhere in further detail [87]. The lower cluster in Figure 2 contained four strains with a gene
encoding an entire sub-type B3 neurotoxin (lower variant in Figure 4, Table S3), and one A2B3 strain
with genes encoding an entire sub-type B3 neurotoxin (fourth variant in Figure 4, Table S3) and
neurotoxin sub-type A2. The B3 strains were associated with wound botulism in UK in 2009 (Table 1),
and the A2B3 strain with foodborne botulism in Italy [59].
The 31 strains with an entire B5 neurotoxin gene were separated into three clusters within the
C. botulinum Group I lineage, but not the C. sporogenes lineage (Figure 2). All but two of these strains
contained an additional botulinum neurotoxin gene. The upper and centre clusters revealed by
SNP analysis (Figure 2) contain A1B5 strains. These strains contained genes potentially encoding
the sub-type B5 neurotoxin (upper sub-type B5 variant in Figure 4) and a sub-type A1 neurotoxin.
Strains were associated with foodborne botulism in Ireland (2006) and the USA, infant botulism in
the UK (1978) and USA, and wound botulism in UK (2009) [65]. In some A1B5 strains the encoded
sub-type B5 neurotoxin is formed in small quantities, but biologically active sub-type B5 neurotoxin
is not formed by a majority of strains [8,46,73,79]. These strains are referred to as A1b5 or A1(B5),
respectively. The lower cluster revealed by SNP analysis (Figure 2) contained 11 strains that possessed
a gene encoding one of two variants of sub-type B5 neurotoxin (centre and lower variants in Figure 4,
Table S3). This included B5, A2B5, A4B5 and B5F2 strains. Most of these strains were involved in
infant botulism cases in UK (in 2012 and 2013; Table 1), Ireland (2014), Sweden and USA [8,25,46,66,82],
but one B5F2 strain was associated with the largest UK outbreak of foodborne botulism (in 1989)
involving the consumption of commercially-prepared hazelnut yoghurt (Table 1) [66,88].
The three strains that possessed a gene encoding botulinum neurotoxin sub-type B6 were located
in a single cluster within the C. sporogenes lineage (see below for further details), with no strains
belonging to the C. botulinum Group I (Figure 2). Previously, Smith et al. reported on eight sub-type
B6 strains, with five strains found in the C. sporogenes lineage and three strains in the C. botulinum
Group I lineage [23]. The genome of seven strains contained a gene encoding botulinum neurotoxin
sub-type B7. Core genome SNP analysis assigned these strains to two clusters within C. botulinum
Group I (Figure 2). The upper cluster contained six sub-type B7 strains and all belonged to MLST ST-34.
Six (different) sub-type B7 strains associated with infant botulism in the eastern USA also belonged
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to MLST ST-34 [89]. The lower cluster contained a single A2B7 strain that had been associated with
foodborne botulism in Italy [59]. Variants were identified of botulinum neurotoxin sub-types B6 and
B7 (Figure 4).
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where they appear in the same order as in this Figure. The sources of the isolates are given in Table S1.
2.4. Diversity and Phylogeny of C. botulinum Group I Type F Strains and Their Botulinum Neurotoxin Genes
Botulinum neurotoxin type F is highly diverse, with eight sub-types (F1 to F8) that differ by
up to 36.2% of amino acid residues. Within sub-type differences are from 0.1–1.7% of amino acid
residues [45]. Strains forming type F neurotoxin are less frequently associated with botulism than
strains forming type A or B neurotoxin, and strains examined in the present study were associated
with foodborne or infant botulism, but not wound botulism (Figure 2). A gene encoding botulinum
neurotoxin type F was located in the genome of 33 strains within the C. botulinum Group I lineage
(but none within the C. sporogenes lineage), including 17 strains with only a type F neurotoxin gene,
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and 16 strains with additional botulinum neurotoxin gene or genes (Figure 2). All genes encoding
botulinum neurotoxin type F were located in an orfX neurotoxin gene cluster. Core SNP analysis
revealed that all strains possessing a gene encoding neurotoxin sub-type F1 clustered together (Figure 2)
and belonged to MLST ST-88 (Table S2). All sequences of botulinum neurotoxin sub-type F1 were
identical (Figure 5), including isolates derived from the first foodborne botulism outbreak associated
with C. botulinum Group I type F that occurred in Denmark [90], and environmental (non-clinical)
isolates. Strains possessing a gene encoding neurotoxin sub-type F2 clustered together (Figure 2) and
belonged to MLST ST-7 and ST-14 (Table S2). Genomes of these strains contained genes encoding
botulinum neurotoxin sub-types F2 and B5, with two closely related variants of botulinum neurotoxin
sub-type F2 identified (Figure 5, Table S3). These strains were associated with foodborne botulism in
UK (1989, Hazelnut yoghurt), and infant botulism in UK (2013), Sweden and USA [8,25,66,88].Toxins 2019, 11, x FOR PEER REVIEW 15 of 29 
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All strains of C. botulinum Group I with genomes encoding botulinum neurotoxin sub-types F4
and/or F5 were non-clinical isolates from Argentina [25,56]. These strains formed five clusters (two each
for F4 and F5 strains, and one including both F4 and F5 strains), indicating spread of these neurotoxin
genes amongst bacteria with a diverse genomic background (Figure 2). The three clusters for strains
with genes encoding botulinum neurotoxin sub-type F4 comprised: A2F2 (one strain); A2F4 and
A2F4F5 (eight strains); and F4 (one strain). All the sequences of botulinum neurotoxin sub-type F4
were identical (Figure 5). The three clusters for strains with genes encoding botulinum neurotoxin
sub-type F5 comprised: A2F4F5 (six strains); A2F5 (one strain); and F5 (one strain). All the sequences
of botulinum neurotoxin sub-type F5 were identical (Figure 5, Table S3).
2.5. Diversity and Phylogeny of Strains within the C. sporogenes Lineage and Their Botulinum Neurotoxin Genes
One hundred and four isolates were assigned to the C. sporogenes lineage according to core genome
SNP analysis (Figure 2). This included several strains previously designated as C. botulinum Group I,
on the basis of their ability to form botulinum neurotoxin. Whilst the genome of a majority of isolates
assigned to the C. sporogenes lineage lacked a botulinum neurotoxin gene, the genome of twenty isolates
possessed a gene that encoded botulinum neurotoxin of either sub-type B1, B2 or B6. These genes
have previously been reported in strains of C. sporogenes [8,22–25]. Examples of strains of C. sporogenes
possessing a botulinum neurotoxin gene that were associated with foodborne, infant and wound
botulism are given in Table 2, whilst other strains possessing a botulinum neurotoxin gene had no
known association with botulism. Strains of C. sporogenes with a gene encoding botulinum neurotoxin
type B were isolated over a wide geographical area (Table S1).
Table 2. Examples of strains within the C. sporogenes lineage associated with outbreaks of botulism.
Strain C. sporogenesCluster *
Botulinum
Neurotoxin Gene Type of Botulism Country (Year) Reference
Prevot 594 upper B2 Foodborne (ham) France (1951) [46]
2345 upper B2 Foodborne (ham) France (1961) [29]
CDC 1632 centre B1 Infant USA (1977) [91]
B2 450 centre B2 Wound (drug abuse) Italy (2009) [59]
AM370 centre B6 Foodborne (salted fish) Australia (1979) [25]
AM1195 centre B6 Infant Australia (1987) [25]
R1125/03 lower B1 Foodborne (meat) UK (2003) [66]
R1135/03 lower B1 Foodborne (meat) UK (2003) [66]
* According to Figure 2.
All sub-type B1, B2 and B6 botulinum neurotoxin genes were located in a ha neurotoxin gene
cluster (Figure 2). The variant of sub-type B1 neurotoxin encoded by C. sporogenes (third variant in
Figure 4, Table S3) can be distinguished from the three variants of sub-type B1 neurotoxin encoded in
the genome of strains of C. botulinum Group I (Figure 4). The variant of sub-type B2 neurotoxin encoded
by most C. sporogenes strains is identical to that encoded by many strains of C. botulinum Group I
(Figure 4). However, one variant is uniquely encoded by C. sporogenes strain B2 450 (CB1071), and an
unusual divergent variant is encoded only by C. sporogenes strain ATCC 51387 (CB1056) (Figure 4).
In the present study, genes encoding botulinum neurotoxin sub-type B6 were located in C. sporogenes,
but not C. botulinum Group I (Figure 2). Genetic analysis carried out previously and also in the present
study showed that the botulinum neurotoxin genes encoded by C. sporogenes are primarily carried on a
plasmid [8,22,24,25,44,91,92]. These strains may lose their ability to form botulinum neurotoxin, and this
phenomenon has been examined further in the present study with strain 2345, where the genome
sequences of the original toxic strain (CB0594) and a non-toxic isolate derived in our laboratory (CB0595)
have been compared. In the original toxic strain (CB0594), the neurotoxin gene is located on a plasmid
very homologous to pCBH of strain Prevot 594 (https://www.ncbi.nlm.nih.gov/nucleotide/CP006901.1).
This is a large plasmid (257 kb), and CB0594 has eight contigs mapping onto that plasmid, for a total of
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240 kb (including the 15 kb contig with the neurotoxin gene cluster). All of these are missing in CB0595,
indicating that the inability to form neurotoxin is due to plasmid loss. An important, but unresolved
question, is why do most C. botulinum Group I strains possess a gene encoding botulinum neurotoxin,
but only few C. sporogenes strains? The answer may be low neurotoxin gene stability (as noted
for strain 2345). A further important question is whether a non-toxigenic strain of C. sporogenes
(or C. botulinum Group I) may acquire a type B neurotoxin gene through horizontal gene transfer.
The C. sporogenes lineage separates into three clusters, each containing isolates that possess and
lack a gene encoding a botulinum neurotoxin (Figure 2). Some of these isolates have been previously
reported to belong to the C. sporogenes lineage [23,25]. Isolates in the upper C. sporogenes cluster,
that possessed a gene encoding botulinum neurotoxin sub-type B2, had been associated with foodborne
botulism involving ham in France (Table 2, Figure 2). Interestingly, the sub-type B2 strain F11 that
was associated with animal (cattle) botulism in France also belonged to MLST ST-54 [29], as did nine
sub-type B2 strains and two non-toxic strains that are located in the upper C. sporogenes cluster in
the present study (Figure 2). The central C. sporogenes cluster included isolates that possessed a gene
encoding botulinum neurotoxin sub-type B1, B2 or B6, and had been involved in foodborne botulism
(Australia), infant botulism (Australia and USA), and wound botulism (Italy) (Table 2, Figure 2).
Two strains (Osaka05 and Okayama2011) not included in the present study, that were associated
with infant botulism in Japan and formed sub-type B6 neurotoxin, were distantly related to strains of
C. botulinum Group I and also belong to the C. sporogenes lineage [7,24,25,46,92]. Interestingly, the lower
C. sporogenes cluster has not been described previously and contains five isolates with a gene encoding
botulinum neurotoxin sub-type B1. It is more distantly separated from the first two clusters (Figure 2).
Strains R1125/03 and R1135/03 were associated with a fatal outbreak of foodborne botulism in the
UK in 2003 involving the consumption of a home-prepared meat dish (“bigos”) brought from Poland
(Tables 1 and 2, Figure 2). Two Polish men shared this meal; one developed botulism in the UK and
subsequently died, while the second was diagnosed with botulism in Poland [66]. Also present in the
lower cluster is strain 2113/01, a non-clinical UK isolate from an unopened can of infant formula that
possessed a gene encoding botulinum neurotoxin sub-type B1 [93,94]. Jacobson et al. [68] reported on
four additional strains located in MLST STs associated with the C. sporogenes lineage. Three strains
(14842, 14843 and 14844) belonged to ST-5, and one strain (A207) belonged to ST-17. Those belonging
to ST-5 were reported to be A(B) strains with a unique neurotoxin cluster arrangement, while the ST-17
strain was reported to form sub-type A1 neurotoxin [68]. It was noted that these strains were distinct
from the other C. botulinum Group I strains analysed [68]. The present study and previous work [24]
both place ST-5 and ST-17 within the C. sporogenes lineage.
2.6. Impact of Genomic and Physiological Variability on the Botulism Risk
Bacterial genomics, the identification of distinct lineages and clusters, and the characterisation
of strains within distinct lineages/clusters can make an important contribution to improved risk
assessments and the prevention of botulism. Several clusters identified in the present study demonstrate
a bias in terms of association with foodborne, infant or wound botulism, or are dominated by non-clinical
(environmental) isolates (Figure 2). For example, many strains in the upper cluster of sub-type A2
strains are associated with infant botulism, while all strains in the lower cluster of sub-type A2
strains are non-clinical (environmental) isolates (Figure 2). Strains associated with foodborne botulism
were widely distributed amongst many clusters, while strains associated with wound botulism were
located in a relatively limited number of clusters (Figure 2). From this it might be inferred that strains
possessing botulinum neurotoxin-encoding genes in certain clusters present a greater risk of botulism,
or even certain types of botulism, than strains in other clusters. However, it could also be the case
that the patterns observed merely represent opportunity, and that all strains that form botulinum
neurotoxin have a similar potential to cause foodborne, infant or wound botulism. Investigating
this further is not part of the present study but represents an important area for future endeavours
that could include genome-wide association studies allied with physiological studies to dissect the
mechanisms key to pathogenicity and pathogen transmission.
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There are, however, two pieces of evidence that suggest that strains within the C. botulinum
Group I lineage currently present a greater botulism risk than strains within the C. sporogenes lineage.
Firstly, a greater fraction of strains within the C. botulinum Group I lineage have been associated
with foodborne, infant and wound botulism, and secondly a greater proportion of strains in the
C. botulinum Group I lineage possess a gene encoding botulinum neurotoxin (Figure 2). However,
detailed information on physiological differences between neurotoxin-forming strains in the C. botulinum
Group I and C. sporogenes lineages is presently lacking, and it is conceivable that circumstances may
arise in the future (e.g., new approaches to food processing) that favour strains in the C. sporogenes
lineage. A detailed analysis of the physiological differences between neurotoxin-forming strains in
the C. botulinum Group I and C. sporogenes lineages is needed to establish whether it is necessary to
conduct separate risk assessments for neurotoxigenic strains of C. botulinum Group I and C. sporogenes.
C. botulinum Group I spores are of high thermal resistance and the target of the Botulinum cook
(121 ◦C/3 min) given to low acid canned foods. For many decades, C. sporogenes has been used as a
surrogate for C. botulinum Group I in food sterilisation tests [7,14,17,19]. In particular, spores of the
nontoxigenic putrefactive anaerobe strain PA3679 are reported to have a higher thermal resistance
than spores of C. botulinum Group I and are widely used in the validation of thermal processes in the
food industry. This strain is generally referred to as a strain of C. sporogenes and does not possess
a botulinum neurotoxin gene. There appear to be several versions of strain PA3679. Weigand et al.
reported their version to align with C. sporogenes strains, while Brown et al. reported that their version
was more closely related to strains of C. botulinum Group I than to strains of C. sporogenes [14,24].
Further studies carried out on a number of isolates labelled “PA3679” confirmed strain heterogeneity.
While some isolates (e.g., 1961-62, 2007) had low spore thermal resistance and genetically resembled
C. sporogenes, other isolates (e.g., Camp, UW, FDA, 1961-64) had high spore thermal resistance and
genetically resembled C. botulinum Group I [7,19]. In the present study, strain PA3679 isolate Camp
(CB1254) was located in the C. botulinum Group I lineage (Figure 2); thus, this isolate appears to be a
non-toxigenic strain of C. botulinum Group I rather than a strain of C. sporogenes.
Clostridium spores include a large store of pyridine-2, 6-dicarboxylic acid (DPA) in a 1:1 chelate
with calcium ions within their core which promotes spore thermal resistance [95]. DPA uptake into the
spore core is regulated by the spoVA operon [96,97]. Recently a spoVA2mob operon on a transposon
identified in Bacillus was associated with a raised DPA content and an increase in spore thermal
resistance [98]. Strain PA3679 isolate Camp had a second spoVA operon, and this was identified as one
factor contributing to the elevated thermal resistance of spores of this strain [12]. In the present study,
bioinformatic analysis revealed that a second spoVA operon (spoVA2) was present in 56% of strains in
the C. botulinum Group I lineage, but only 3% of strains in the C. sporogenes lineage (Table S2, Figure S1),
potentially alluding to a high spore thermal resistance for many strains in the C. botulinum Group I
lineage. Strains with a second spoVA operon (spoVA2) formed five clusters in the C. botulinum Group I
lineage and one cluster in the C. sporogenes lineage (Table S2, Figure S1). When conducting challenge
tests or validating thermal processes for C. botulinum, it is therefore prudent to select appropriate
strains from C. botulinum Group I and/or C. sporogenes that takes account of genomic/physiological
variability. Toxic and non-toxic strains have been identified in both lineages. The use of strains located
within the C. sporogenes lineage may not be appropriate for thermal death studies.
2.7. Pan-genome Comparison of C. botulinum Group I and C. sporogenes Genomic Clusters and Identification of
C. botulinum Group I- and C. sporogenes-specific Genes
The 556 genomes examined in this study separated into a distinct C. botulinum Group I lineage,
consisting of 452 genomes, and a C. sporogenes lineage that comprised two previously known
clusters of 94 genomes and an additional new cluster of ten genomes (Figure 2). In a previous
study, Williamson et al. [56] provided primers to distinguish C. botulinum Group I from C. sporogenes.
When tested in silico against all genomes used in the present study, the primer pair correctly distinguished
the previously known C. botulinum Group I and C. sporogenes clusters, but failed to correctly identify the
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additional (lower) C. sporogenes cluster, as strains within this cluster were positive for the C. botulinum
PCR product (10/10) and negative for the C. sporogenes PCR product (9/10). Similarly, Weigand et al. [24]
performed genome analysis for C. botulinum Group I and C. sporogenes, and identified 11 candidate
genes for a species-specific PCR. These were also tested against the 452 C. botulinum Group I and 104
C. sporogenes genomes used in the present study. None of the primer sets was able to correctly amplify
all genomes tested; the nifS primers detected all C. sporogenes genomes, but also amplified 29 of the
C. botulinum Group I genomes, whereas the spoVB primers correctly identified 452 C. botulinum Group I
and 94 C. sporogenes genomes, but failed to amplify the additional (lower) C. sporogenes cluster. As both
genes were present in all genomes, it might be that the efficiency could be improved by the selection
of new primers. The other nine genes [24], performed less well, either amplifying a larger number of
C. botulinum genomes (thiHG), or not or only partially amplifying the new C. sporogenes cluster.
Pangenome analysis was used to search for genes for C. botulinum Group I and C. sporogenes.
The pangenome of the combined 556 genomes was generated using Prokka-annotated genome sequences
and the Roary software package [99], followed by identification of lineage-specific genes defined.
The pangenome consisted of 18,731 annotated features, with 2420 annotated features present in >95% of
the genomes (core genome). The distribution of genes linked to the position in the core genome-based
phylogenetic tree is shown in Figure 6A. Due to the different sizes of the groups, lineage specificity
was initially set at present in ≥90% (over-represented) or present in ≤10% (under-represented) for
C. botulinum Group I, and ≥80%/≤20% for the larger 94-genome C. sporogenes cluster, and ≥70%/≤30% for
the smaller 10-genome C. sporogenes cluster. This identified 224 features over-represented in C. botulinum,
and 79 features over-represented in C. sporogenes. The relative position of features specific for C. botulinum
Group I and C. sporogenes were plotted using the complete genomes of C. botulinum Group I strain ATCC
19397 and C. sporogenes strain NCIMB 10696 (Figure 6B), and these features were spread throughout the
chromosome, similar to the two C. botulinum Group II lineages [2].Toxins 2019, 11, x FOR PEER REVIEW 20 of 29 
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Of the over-represented features for C. botulinum Group I and C. sporogenes, 35 showed a perfect
distribution for C. botulinum and 14 did likewise for C. sporogenes. These were further tested at the
nucleotide level using BLAST, resulting in 13 genes specific for C. botulinum Group I and four genes
specific for C. sporogenes, defined by >99% specificity (Table S4). These genes comprise candidates for
a future PCR assay to distinguish C. botulinum Group I and C. sporogenes, but the development and
testing of such an assay falls outside the scope of this study.
3. Conclusions
This co parative genomic investigation of 556 highly diverse strains of C. botulinum Group
I and C. sporogenes (including 417 newly sequenced strains) has analysed population diversity,
structure, and spread, and established novel relationships between whole genome lineage, botulinum
neurotoxin sub-type variant, association with foodborne, infant and wound botulism, epidemiology,
and geographic origin. The impact of genomic and physiological variability on the botulism risk has
been evaluated. Strains had up to three botulinum neurotoxin genes (of types A, B and/or F), but no
novel botulinum neurotoxin genes (serotypes or sub-types) were discovered. This may suggest a
limited number of unknown botulinum neurotoxin genes (serotypes or sub-types) within the genomes
of C. botulinum Group I and C. sporogenes. The present study described novel botulinum neurotoxin
sub-type variants, each with a unique amino acid sequence. Core genome SNPs analysis identified
two major lineages; C. botulinum Group I (most strains possessed neurotoxin gene(s) of types A, B
and/or F) and C. sporogenes (some strains possessed a type B neurotoxin gene). Both lineages contained
strains responsible for foodborne, infant and wound botulism. An additional new C. sporogenes cluster
was discovered that included five strains with a gene encoding botulinum neurotoxin sub-type B1.
There was significant evidence of horizontal transfer of botulinum neurotoxin genes between distantly
related bacteria. Each lineage also included strains that lacked a botulinum neurotoxin-encoding
gene. The pan-genome of C. botulinum Group I and C. sporogenes contained 18,731 annotated features,
with a core genome of 2420 annotated features (present in >95% of genomes), and 224 and 79 features
over-represented in the genomes of C. botulinum Group I and C. sporogenes, respectively. There were
no integration hotspots, with lineage-specific features located throughout the genomes. The genome
sequences are also a valuable resource to future research endeavours, for example, on pathogen
biology, the evolution of bacteria and their neurotoxin genes, and improved pathogen detection
and discrimination. When investigating outbreaks of human or animal botulism or carrying out
surveillance studies, it is vital to establish the C. botulinum Group and lineage of the bacterium involved,
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and the associated botulinum neurotoxin(s). The increased availability of whole genome sequences
for C. botulinum Group I and C. sporogenes (this study) and C. botulinum Group II (previously [2])
gives a greater value to genetic tests. Improved PCR tests can be used to rapidly detect and identify
the bacterium present, its lineage, and botulinum neurotoxin gene(s). While the genome sequences
enable enhanced isolate discrimination and detailed epidemiological investigation. This may support
enhanced risk assessments and prevent and/or minimise botulism outbreaks.
4. Materials and Methods
4.1. Strains of C. botulinum Group I and C. sporogenes
The genomes of 556 strains were examined (417 newly sequenced strains and 139 genomes from
public sources, Table S1). The newly sequenced strains were isolated in the authors’ laboratory or
kindly provided by colleagues (B. Dorner, T. Grenda, C. Hatheway, V. Broussolle, A. East, P. McClure,
T. Roberts, H. Tranter, J. Crowther, P. Barrett, L. Taylor and M. Wictome; Table S1). The strains were
isolated over a period of more than 100 years, from 24 countries throughout Europe, Asia, Africa,
Australasia, north America and south America (Figure 1). Seventy-three strains were isolated following
outbreaks of foodborne botulism, 70 strains were associated with infant botulism, 82 strains were
associated with wound botulism, and 139 strains were non-clinical isolates not associated with human
botulism (Table S1). The status of the remaining strains is unknown. Based on their genome sequence,
452 strains were assigned to C. botulinum Group I and 104 strains to C. sporogenes. This led to some
strains now being considered as C. botulinum Group I and not C. sporogenes, or vice-versa. Most of the
strains assigned to C. botulinum Group I possessed a botulinum neurotoxin gene or genes, while some
of the strains assigned to C. sporogenes possessed a botulinum neurotoxin gene. The strains possessed
up to three botulinum neurotoxin genes (Table 3). In this study, strains are referred to by their type or
sub-type of botulinum neurotoxin gene(s). Thus, for example, B5F2 strains possess genes encoding
botulinum neurotoxin sub-types B5 and F2. It was not established whether all neurotoxin genes were
associated with formation of botulinum neurotoxin.
Table 3. Neurotoxin genes present in the genomes of isolates of C. botulinum Group I and C. sporogenes
(see Table S1 for further details of the isolates).
Botulinum Neurotoxin Gene Sub-Type Number of Strains Included in This Study
A1 64
A1 B5 20
A2 114
A2 B2 1
A2 B3 1
A2 B5 1
A2 B7 1
A2 F4 3
A2 F5 1
A2 F4 F5 6
A3 9
A4 B5 2
A5 B2 44
A5 B3 8
B1 37
B2 73
B2 FA 1
B3 30
B5 2
B5 F2 6
B6 3
B7 6
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Table 3. Cont.
Botulinum Neurotoxin Gene Sub-Type Number of Strains Included in This Study
F1 14
F4 1
F5 1
F8 1
none 107
TOTAL 556
4.2. Genomic DNA Preparation and Whole Genome Sequencing
DNA extraction was performed by following the traditional Gram-positive cell lysis procedures [2].
Whole genome sequencing of the C. botulinum gDNA samples was carried out at the Earlham Institute,
UK [2]. Briefly, libraries were assembled with 1ng of DNA. Libraries were constructed using unique 9 bp
dual index combinations allowing samples to be multiplexed. Libraries were pooled then sequenced
with a 2 × 250 bp read metric on an Illumina HiSeq 2500 sequencer.
4.3. Genome Assembly and Quality Control
Shovill version 1.0.4 (https://github.com/tseemann/shovill) with the Spades 3.13.0 assembler
module [100] were used to assemble genome sequences, with contigs smaller than 200 bp and coverage
lower than five-fold excluded. Assembly metrics were obtained using QUAST version 4.6 [101] with
genome size, N50, L50 and number of contigs used for quality assessment of the assemblies. Genome
assemblies were annotated using Prokka version 1.13 [102]. Multilocus Sequence Typing (MLST) was
done using mlst version 2.16.0 (https://github.com/tseemann/mlst) and the sequence profiles from the
C. botulinum PubMLST homepage (https://pubmlst.org/cbotulinum/). The Genbank/SRA accession
numbers for genome assemblies, FASTQ reads, and source information are provided in Table S1.
4.4. Identification of Botulinum Neurotoxin Sub-Types and Accessory Protein Configuration
The Prokka annotated features were searched with representatives of the A, B, C, D, E, F, G, FA, X
and Ebont/J toxins [45,69] as described in Brunt et al. [2]. Gene sequences representing incomplete,
fragmented and inactivated toxin genes were manually extracted from the individual genome sequences,
and frameshifts/stop codons manually repaired to obtain the amino acid sequences for comparison.
Toxins were assigned to specific sub-types by alignment of the amino acid sequences with the toxin
reference types [45] using the MUSCLE module of MEGA7 [72], and subsequent generation of a
Neighbour-Joining tree and clustering with reference toxins, with Gaps/Missing data set to pairwise
deletion. Accessory genes were identified using BLAST using reference sequences [3].
4.5. Pangenome Analyses, Target Gene Identification and in silico PCR
The pangenome of C. botulinum Group I and closely related C. sporogenes was identified using
Roary version 3.13 [99] and was based on the Prokka-annotated genome assemblies, with 80% and
90% BLAST cut-off percentages, and paralog clustering both switched off and on [103], as described
previously for C. botulinum Group II [2]. Briefly, the Roary-outputs were analysed using Scoary [104]
with a Bonferroni corrected p-value cut-off of 0.05. For C. botulinum Group I, genes were considered
over- or under-represented if either present in ≥90% of the tester group and less than ≤10% of the
comparator group, or vice versa. However, due to the different group size, lineage specificity was
initially set at ≥80%/≤20% for the larger 94-genome C. sporogenes cluster, and ≥70%/≤30% for the
smaller 10-genome C. sporogenes cluster. The plots for the pangenome distribution were generated
with roary plots (https://github.com/sanger-pathogens/Roary/tree/master/contrib/roary_plots). In silico
PCR was performed using MIST [105].
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4.6. Core Genome SNPs Analysis and Phylogenetic Trees
Phylogenetic trees were generated using core genome SNPs and the ParSNP program [70] with
settings described previously [106]. Phylogenetic trees were annotated using Figtree (http://tree.bio.ed.ac.
uk/software/figtree/) and MEGA7 [72].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/12/9/586/s1,
Figure S1 (Presence of second spoVA operon (spoVA2) in strains of C. botulinum Group I and C. sporogenes (genome
phylogeny as in Figure 2, further details Table S2)), Table S1 (Genome sequences of C. botulinum Group I and
C. sporogenes used in this study), Table S2 (Strain ID Figure 2), Table S3 (Strain ID Figures 3–5), Table S4 (Candidates
genes for PCR assay to distinguish C. botulinum Group I and C. sporogenes).
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